stockrowDefinium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) Operating cash flow
Definium Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$131.6M, compared with −$79.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$168.0M. Over the past ten years it has ranged from −$131.6M (fiscal 2025) to −$19.7K (fiscal 2016) — the current reading is the lowest in ten years. Operating cash flow has fallen for 7 consecutive fiscal years. Definium Therapeutics, Inc. ranks 525th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$131.6M | — |
| FY2024 | −$79.1M | — |
| FY2023 | −$64.4M | — |
| FY2022 | −$50.1M | — |
| FY2021 | −$45.8M | — |
| FY2020 | −$23.6M | — |
| FY2019 | −$3.2M | — |
| FY2018 | −$531.3K | — |
| FY2017 | −$532.8K | — |
| FY2016 | −$19.7K | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$52.8M | — |
| Mar 2026 | −$42.6M | — |
| Dec 2025 | −$43.0M | — |
| Sep 2025 | −$29.6M | — |
| 25 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$89.4M |
| ABCL AbCellera Biologics Inc. compare | −$94.9M |
| ERAS Erasca, Inc. compare | −$98.0M |
| DFTX Definium Therapeutics, Inc. | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.2M |
| EWTX Edgewise Therapeutics, Inc. compare | −$201.9M |
| RLAY Relay Therapeutics, Inc. compare | −$214.0M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item